ABOUT
GSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.
We have 3 global businesses that research, develop and manufacture innovative pharmaceutical medicines, vaccines and consumer healthcare products.
Our goal is to be one of the world’s most innovative, best performing and trusted healthcare companies.
Our values and expectations are at the heart of everything we do and help define our culture – so that together we can deliver extraordinary things for our patients and consumers and make GSK a brilliant place to work.
Our values are Patient focus, Transparency, Respect, Integrity.
Our expectations are Courage, Accountability, Development, Teamwork.
What we do
We aim to bring differentiated, high-quality and needed healthcare products to as many people as possible, with our 3 global businesses, scientific and technical know-how and talented people.
NEWS
GSK unveils plan for one of Europe’s largest life science campuses in Stevenage
GSK has announced that it has formally started the process of seeking a development partner to transform land within the company’s existing 92-acre Research & Development site in Stevenage into one of Europe’s largest ‘clusters’ for biotechnology and other...
US Food and Drug Administration (FDA) grants priority review of belantamab mafodotin for patients with relapsed or refractory multiple myeloma
US Food and Drug Administration (FDA) grants priority review of belantamab mafodotin for patients with relapsed or refractory multiple myeloma Biologics License Application based on results from the pivotal DREAMM-2 study of immunoconjugate targeting B-cell maturation...
Dovato (dolutegravir/lamivudine), the once-daily, single-pill, 2-drug regimen for the treatment of HIV-1 infection, granted marketing approval by Japan Ministry of Health, Labour and Welfare
Issued: Japan and UK ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, announced that it has obtained approval of Dovato (dolutegravir 50 mg/lamivudine 300 mg) from the Japan Ministry of...
Interested in joining UKSPA?
Gain exclusive access to members only resources, research papers, statistics and data – as well as discounted or even free entry to the conferences and events we hold through the year.